| Cat. No. |
Product Name |
Information |
| PC-72237 |
Myricetin
ENPP1 inhibitor
|
Myricetin (Myricetol, Myricitin) is a flavonoid compound with antioxidant properties, inhibits ENPP1 enzymatic activity with IC50 of 4.8 uM. |
| PC-72235 |
ENPP1 inhibitor QS1
ENPP1 inhibitor
|
ENPP1 inhibitor QS1 (QPS1) is a potent, selective non-competitive inhibitor of Ectonucleotide pyrophosphatase/PDE1 (NPP1, ENPP1) with Ki of 59.3 nM.
QPS1 also significantly inhibited the K121Q NPP1 gene variant with Ki of 59.2 nM. |
| PC-72175 |
OXS007417
AML differentiation inducer
|
OXS007417 (OXS 007417) is a small moelcule that induces differentiation of AML cells in vitro (CD11b increasein HL-60 cell EC50=48 nM) and shows antitumor effects in vivo. |
| PC-72155 |
L-Propargylglycine
CSE inhibitor
|
L-Propargylglycine (L-PAG) is the most commonly used, covalently irreversible inhibitor inhibitor of cystathionine γ-lyase (CSE). |
| PC-72154 |
CSE inhibitor 43
CSE inhibitor
|
CSE inhibitor 43 is a novel potent, selective, competitive inhibitor of cystathionine γ-lyase (CSE) inhibitor with IC50 of 1.2 uM. |
| PC-72138 |
NSC 773097
|
NSC 773097 is a RITA analog that produces hyperselective cytotoxicity while maintaining antitumor efficacy (A498 cell IC50=130 nM). |
| PC-72132 |
BD50265
GPR52 agonist
|
BD50265 (BD 50265) is a potent small-molecule GPR52 agonist. |
| PC-72131 |
BD442618
GPR52 agonist
|
BD442618 (BD 442618) is a potent small-molecule GPR52 agonist. |
| PC-72130 |
WO-459
GPR52 agonist
|
WO-459 (WO459) is the first potent and orally available agonist of GPR52 with pEC50 of 7.53. |
| PC-72129 |
GPR52 antagonist E7
GPR52 antagonist
|
GPR52 antagonist E7 is a novel Gpr52 antagonist, shows significant inhibitory effect on WO-459 (100 nM)-induced cAMP elevation in HEK293/GPR52 cells with IC50 of 12.0 uM. |
| PC-72127 |
PW0787
GPR52 agonist
|
PW0787 (PW 0787) is a potent, selective, brain-penetrant GPR52 agonist with EC50 of 135 nM in cAMP assays in HEK293 cells. |
| PC-72124 |
AGF347
SHMT2 inhibitor
|
AGF347 (AGF-347) is a small molecule inhibitor targeting mitochondrial C1 metabolism at SHMT2 (in vitro Ki=2.19 uM), also directly targers the purine biosynthetic enzymes GARFTase (Ki=3.13 uM) and AICARFTase (Ki=3.72 uM), and SHMT1 (Ki=2.91 uM). |
